Seres Price To Sales Ratio vs Roic Analysis

MCRB Stock

USD 0.78 0.01 1.27%

Seres Therapeutics financial indicator trend analysis is much more than just breaking down Seres Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Seres Therapeutics is a good investment. Please check the relationship between Seres Therapeutics Price To Sales Ratio and its Roic accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Seres Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.

Price To Sales Ratio vs Roic

Price To Sales Ratio vs Roic Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Seres Therapeutics Price To Sales Ratio account and Roic. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Seres Therapeutics' Price To Sales Ratio and Roic is -0.05. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Roic in the same time period over historical financial statements of Seres Therapeutics, assuming nothing else is changed. The correlation between historical values of Seres Therapeutics' Price To Sales Ratio and Roic is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of Seres Therapeutics are associated (or correlated) with its Roic. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Roic has no effect on the direction of Price To Sales Ratio i.e., Seres Therapeutics' Price To Sales Ratio and Roic go up and down completely randomly.

Correlation Coefficient

-0.05

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Seres Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Seres Therapeutics sales, a figure that is much harder to manipulate than other Seres Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Roic

Return on Invested Capital, a profitability ratio that measures the return that an investment generates for those who have provided capital, such as debt holders and equity holders.

Most indicators from Seres Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Seres Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Seres Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.The current year's Selling General Administrative is expected to grow to about 106 M, whereas Issuance Of Capital Stock is forecasted to decline to about 11 M.

	2024	2025 (projected)
Non Recurring	1.3M	1.2M
Reconciled Depreciation	5.6M	5.5M

Non Recurring Reconciled Depreciation

Seres Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Current Assets	Total Liab	Total Current Assets	Common Stock	Short Long Term Debt Total	Other Liab	Current Deferred Revenue	Long Term Debt	Common Stock Total Equity	Non Current Liabilities Total	Other Stockholder Equity	Property Plant And Equipment Gross
Total Assets		0.7	0.8	0.29	0.69	0.14	-0.82	0.65	0.86	0.74	0.56	0.66	0.85	0.76	0.48	0.75	0.92	0.82	0.64	0.71	0.44	0.61	0.83	0.71	0.78	0.65
Other Current Liab	0.7		0.91	-0.27	0.97	0.64	-0.91	0.52	0.69	0.94	0.84	0.53	0.37	0.94	0.33	0.91	0.47	0.93	0.96	0.47	0.05	0.9	0.93	0.9	0.91	0.94
Total Current Liabilities	0.8	0.91		-0.21	0.93	0.52	-0.97	0.56	0.76	0.93	0.85	0.56	0.53	0.98	0.54	0.97	0.63	0.98	0.91	0.72	0.38	0.91	0.98	0.94	0.97	0.91
Total Stockholder Equity	0.29	-0.27	-0.21		-0.34	-0.55	0.2	0.25	0.09	-0.25	-0.36	0.25	0.63	-0.23	-0.01	-0.34	0.55	-0.13	-0.36	-0.03	0.26	-0.41	-0.11	-0.39	-0.16	-0.37
Property Plant And Equipment Net	0.69	0.97	0.93	-0.34		0.72	-0.9	0.45	0.61	0.98	0.89	0.45	0.33	0.94	0.3	0.95	0.43	0.93	0.98	0.56	0.11	0.94	0.92	0.95	0.88	0.99
Net Debt	0.14	0.64	0.52	-0.55	0.72		-0.49	-0.18	-0.06	0.71	0.76	0.16	-0.3	0.6	-0.07	0.57	-0.18	0.56	0.77	0.11	-0.24	0.75	0.52	0.59	0.5	0.78
Retained Earnings	-0.82	-0.91	-0.97	0.2	-0.9	-0.49		-0.56	-0.78	-0.9	-0.78	-0.63	-0.52	-0.95	-0.57	-0.94	-0.62	-0.97	-0.88	-0.73	-0.4	-0.88	-0.97	-0.91	-0.97	-0.87
Accounts Payable	0.65	0.52	0.56	0.25	0.45	-0.18	-0.56		0.7	0.39	0.12	0.23	0.71	0.44	0.54	0.46	0.69	0.51	0.31	0.62	0.36	0.22	0.55	0.41	0.51	0.32
Cash	0.86	0.69	0.76	0.09	0.61	-0.06	-0.78	0.7		0.61	0.49	0.57	0.77	0.72	0.54	0.73	0.82	0.74	0.58	0.59	0.38	0.56	0.76	0.7	0.75	0.56
Non Current Assets Total	0.74	0.94	0.93	-0.25	0.98	0.71	-0.9	0.39	0.61		0.91	0.56	0.39	0.96	0.28	0.95	0.5	0.95	0.97	0.58	0.16	0.95	0.94	0.95	0.9	0.98
Non Currrent Assets Other	0.56	0.84	0.85	-0.36	0.89	0.76	-0.78	0.12	0.49	0.91		0.4	0.22	0.9	0.19	0.88	0.34	0.85	0.95	0.37	0.05	0.97	0.82	0.88	0.8	0.95
Other Assets	0.66	0.53	0.56	0.25	0.45	0.16	-0.63	0.23	0.57	0.56	0.4		0.57	0.64	0.28	0.53	0.62	0.65	0.49	0.39	0.39	0.5	0.67	0.5	0.7	0.44
Cash And Short Term Investments	0.85	0.37	0.53	0.63	0.33	-0.3	-0.52	0.71	0.77	0.39	0.22	0.57		0.47	0.49	0.45	0.99	0.55	0.27	0.57	0.59	0.24	0.58	0.39	0.52	0.27
Common Stock Shares Outstanding	0.76	0.94	0.98	-0.23	0.94	0.6	-0.95	0.44	0.72	0.96	0.9	0.64	0.47		0.45	0.97	0.57	0.98	0.96	0.59	0.26	0.95	0.97	0.95	0.97	0.94
Other Current Assets	0.48	0.33	0.54	-0.01	0.3	-0.07	-0.57	0.54	0.54	0.28	0.19	0.28	0.49	0.45		0.44	0.5	0.52	0.29	0.61	0.72	0.3	0.55	0.39	0.55	0.25
Total Liab	0.75	0.91	0.97	-0.34	0.95	0.57	-0.94	0.46	0.73	0.95	0.88	0.53	0.45	0.97	0.44		0.55	0.95	0.94	0.67	0.29	0.94	0.94	1.0	0.91	0.95
Total Current Assets	0.92	0.47	0.63	0.55	0.43	-0.18	-0.62	0.69	0.82	0.5	0.34	0.62	0.99	0.57	0.5	0.55		0.64	0.39	0.62	0.58	0.36	0.67	0.49	0.61	0.39
Common Stock	0.82	0.93	0.98	-0.13	0.93	0.56	-0.97	0.51	0.74	0.95	0.85	0.65	0.55	0.98	0.52	0.95	0.64		0.93	0.65	0.38	0.92	1.0	0.92	0.98	0.92
Short Long Term Debt Total	0.64	0.96	0.91	-0.36	0.98	0.77	-0.88	0.31	0.58	0.97	0.95	0.49	0.27	0.96	0.29	0.94	0.39	0.93		0.45	0.08	0.98	0.92	0.94	0.89	0.99
Other Liab	0.71	0.47	0.72	-0.03	0.56	0.11	-0.73	0.62	0.59	0.58	0.37	0.39	0.57	0.59	0.61	0.67	0.62	0.65	0.45		0.7	0.48	0.67	0.63	0.66	0.51
Current Deferred Revenue	0.44	0.05	0.38	0.26	0.11	-0.24	-0.4	0.36	0.38	0.16	0.05	0.39	0.59	0.26	0.72	0.29	0.58	0.38	0.08	0.7		0.17	0.4	0.24	0.4	0.09
Long Term Debt	0.61	0.9	0.91	-0.41	0.94	0.75	-0.88	0.22	0.56	0.95	0.97	0.5	0.24	0.95	0.3	0.94	0.36	0.92	0.98	0.48	0.17		0.9	0.94	0.9	0.97
Common Stock Total Equity	0.83	0.93	0.98	-0.11	0.92	0.52	-0.97	0.55	0.76	0.94	0.82	0.67	0.58	0.97	0.55	0.94	0.67	1.0	0.92	0.67	0.4	0.9		0.91	0.98	0.9
Non Current Liabilities Total	0.71	0.9	0.94	-0.39	0.95	0.59	-0.91	0.41	0.7	0.95	0.88	0.5	0.39	0.95	0.39	1.0	0.49	0.92	0.94	0.63	0.24	0.94	0.91		0.88	0.95
Other Stockholder Equity	0.78	0.91	0.97	-0.16	0.88	0.5	-0.97	0.51	0.75	0.9	0.8	0.7	0.52	0.97	0.55	0.91	0.61	0.98	0.89	0.66	0.4	0.9	0.98	0.88		0.87
Property Plant And Equipment Gross	0.65	0.94	0.91	-0.37	0.99	0.78	-0.87	0.32	0.56	0.98	0.95	0.44	0.27	0.94	0.25	0.95	0.39	0.92	0.99	0.51	0.09	0.97	0.9	0.95	0.87

Click cells to compare fundamentals

Seres Therapeutics Account Relationship Matchups

Seres Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	342.9M	354.9M	348.8M	358.6M	412.4M	225.8M
Other Current Liab	21.7M	38.5M	105.0M	80.6M	92.7M	97.3M
Total Current Liabilities	46.4M	82.3M	85.6M	98.7M	113.5M	119.1M
Total Stockholder Equity	174.8M	131.5M	10.8M	(44.9M)	(40.4M)	(38.4M)
Property Plant And Equipment Net	22.9M	36.1M	134.0M	132.3M	152.1M	159.7M
Net Debt	(75.3M)	(130.8M)	(440K)	86.0M	98.9M	103.8M
Retained Earnings	(548.8M)	(614.4M)	(864.5M)	(978.2M)	(880.4M)	(836.4M)
Accounts Payable	4.0M	13.7M	17.4M	3.6M	4.2M	6.7M
Cash	116.0M	180.0M	163.0M	128.0M	147.2M	93.9M
Non Current Assets Total	74.2M	51.2M	154.0M	183.2M	210.7M	221.2M
Cash And Short Term Investments	253.6M	290.7M	181.3M	128.0M	147.2M	156.3M
Common Stock Shares Outstanding	79.8M	91.7M	108.1M	128.0M	147.2M	154.6M
Other Current Assets	11.5M	25.8M	13.4M	9.1M	10.5M	10.4M
Total Liab	168.2M	223.4M	338.0M	403.5M	464.0M	487.2M
Total Current Assets	268.8M	303.6M	194.8M	175.4M	201.7M	166.7M
Common Stock	91K	92K	125K	135K	155.3K	163.0K
Short Long Term Debt Total	40.8M	49.2M	162.6M	213.9M	246.0M	258.3M
Other Liab	94.4M	86.6M	98.5M	93.9M	108.0M	78.0M
Current Deferred Revenue	22.6M	16.8M	4.3M	7.7M	8.9M	13.6M
Long Term Debt	24.6M	24.6M	50.6M	101.5M	116.8M	122.6M
Common Stock Total Equity	70K	91K	92K	125K	143.8K	150.9K
Liabilities And Stockholders Equity	342.9M	354.9M	348.8M	358.6M	412.4M	245.7M
Non Current Liabilities Total	121.8M	141.1M	252.4M	304.8M	350.5M	368.0M
Other Stockholder Equity	723.5M	745.8M	875.2M	933.2M	1.1B	1.1B
Property Plant And Equipment Gross	22.9M	36.1M	134.0M	183.4M	210.9M	221.4M
Accumulated Other Comprehensive Income	(27.7M)	(47K)	(60K)	(12K)	(13.8K)	(14.5K)
Short Term Debt	5.6M	13.2M	4.1M	6.7M	7.7M	7.1M
Property Plant Equipment	19.5M	13.9M	36.1M	23.0M	26.4M	21.7M
Net Tangible Assets	(48.3M)	174.8M	131.5M	10.8M	9.7M	9.2M
Retained Earnings Total Equity	(459.6M)	(548.8M)	(614.4M)	(864.5M)	(778.1M)	(739.2M)
Capital Surpluse	411.3M	723.5M	745.8M	875.2M	1.0B	552.2M
Non Current Liabilities Other	97.1M	116.5M	201.8M	1.6M	1.9M	1.8M
Capital Lease Obligations	15.7M	24.6M	111.5M	112.4M	129.3M	135.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GM	General Motors
C	Citigroup

When determining whether Seres Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Seres Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Seres Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Seres Therapeutics Stock:

How To Invest In Seres

Details

Is Seres Stock a good investment?

Details

What is Seres Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Seres Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.

You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Seres Therapeutics. If investors know Seres will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Seres Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.40)

Revenue Per Share

0.871

Quarterly Revenue Growth

(0.93)

Return On Assets

(0.1)

Return On Equity

(15.56)

The market value of Seres Therapeutics is measured differently than its book value, which is the value of Seres that is recorded on the company's balance sheet. Investors also form their own opinion of Seres Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Seres Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Seres Therapeutics' market value can be influenced by many factors that don't directly affect Seres Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Seres Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Seres Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seres Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Seres Price To Sales Ratio vs Roic Analysis

Price To Sales Ratio vs Roic

Price To Sales Ratio vs Roic Correlation Analysis

Correlation Coefficient

Price To Sales Ratio

Roic

Seres Therapeutics fundamental ratios Correlations

Seres Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Seres Therapeutics fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Liabilities Total	+ 1.0	Total Liab
Common Stock Total Equity	+ 1.0	Common Stock
Property Plant And Equipment Gross	+ 0.99	Property Plant And Equipment Net
Total Current Assets	+ 0.99	Cash And Short Term Investments
Property Plant And Equipment Gross	+ 0.99	Short Long Term Debt Total
Common Stock Shares Outstanding	+ 0.98	Total Current Liabilities

Other Stockholder Equity	- 0.97	Retained Earnings
Common Stock Total Equity	- 0.97	Retained Earnings
Common Stock	- 0.97	Retained Earnings
Retained Earnings	- 0.97	Total Current Liabilities
Common Stock Shares Outstanding	- 0.95	Retained Earnings
Total Liab	- 0.94	Retained Earnings